Bayer receives approval for new long-term contraceptive Skyla™ in the U.S.
- Details
- Category: Bayer
Bayer HealthCare has received approval from the U.S. Food and Drug Administration (FDA) for its new low dose levonorgestrel-releasing intrauterine system (IUS) called Skyla™ in the U.S.. The new IUS is placed in the uterus for the prevention of pregnancy for up to three years.
Abbott initiates clinical trial of Absorb TM in the United States
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced today the initiation of the ABSORB III clinical trial in patients in the United States. This randomized, controlled trial is designed to enroll approximately 2,250 patients, the majority in the United States, and compare the performance of Abbott's drug eluting Absorb TM Bioresorbable Vascular Scaffold (BVS) device to the company's XIENCE TM family of drug eluting stents.
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced top-line results for four completed Phase III clinical trials for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT2) inhibitor being studied for treatment of patients with Type 2 Diabetes (T2D).
Abbott completes separation of research-based pharmaceuticals business
- Details
- Category: Abbott
Abbott (NYSE: ABT) has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie will begin trading independently on the New York Stock Exchange today under the symbol "ABBV."
FDA approves ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Atrial fibrillation, the most common type of irregular heartbeat, affects approximately 5.8 million people in the U.S., and results in a five times greater risk of stroke.
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved Signifor® (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative3. Signifor is the first medicine to be approved in the US that addresses the underlying mechanism of Cushing's disease,
GSK forms partnership with Vodafone to help increase childhood vaccination in Mozambique
- Details
- Category: GlaxoSmithKline
GSK has formed a partnership with Vodafone to harness innovative mobile technology to help vaccinate more children against common infectious diseases in Africa. Despite major advances in the funding and availability of vaccines worldwide, it is estimated that up to a fifth of children worldwide still do not receive basic vaccines.
More Pharma News ...
- Roche reports positive studies of MabThera given by subcutaneous injection
- Boehringer Ingelheim and Apexigen sign manufacturing agreement
- Roche and the Innovative Medicines Initiative join forces to promote use of Nobel Prize-winning stem cell technology
- Novo Nordisk to create the world's first all-diabetes professional cycling team
- GSK welcomes the publication of the 2012 Access to Medicines Index
- Sanofi ranks third on the Access to Medicine Foundation's 2012 ATM Index
- Novartis highlights key data in patients with hematologic diseases and breast cancer